相关实验视频

Updated: Jan 16, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

埃托米达通过抑制肝细胞癌细胞中PD-L1表达来提高抗瘤免疫力

Jiali Xu¹, Qing Ji², Yining Chen³

¹Department of Anesthesiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, China; Department of Anesthesiology and Perioperative Medicine, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China.

Cellular and molecular gastroenterology and hepatology

|October 1, 2025

概括

麻醉剂埃托米达被发现可以降低肝癌细胞中的编程死亡配体1 (PD-L1). 这增强了免疫系统的功能.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

麻醉剂埃托米达 (etomidate) 在癌症治疗中显示出潜在的潜力.
以前的研究表明,埃托米达可以减缓肝细胞癌 (HCC) 的进展.
在HCC中,瘤微环境往往具有免疫抑制作用.

研究的目的:

调查埃托米达对HCC中免疫抑制瘤微环境的影响.
阐明埃托米达特调节这种微环境的分子机制.
探索埃托米达在增强HCC免疫治疗中的潜力.

主要方法:

使用了体外和体内模型,包括HCC器官和患者衍生的异种移植.
采用了先进的技术,如飞行时间单细胞细胞计 (CyTOF) 和多重免疫组织化学.
通过流式细胞计量分析细胞反应.

主要成果:

埃托米达抑制了HCC细胞中编程死亡配体1 (PD-L1) 的表达.
在机械上,埃托米达抑制了Janus激酶2/信号转换器和转录3 (JAK2/STAT3) 途径的激活器.
这导致细胞毒性CD8+ T淋巴细胞的透和激活增加.

结论:

埃托米达增强了HCC的抗瘤免疫力.
它增强了免疫检查点阻塞疗法的有效性.
提供了HCC中精密免疫疗法策略的基础.

关键词:

麻醉剂是一种麻醉剂.免疫抑制是一种免疫抑制.免疫治疗是一种免疫疗法.这就是JAK/STAT.瘤微环境瘤微环境

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.